Table 3

Adjusted effect of diabetes status on CRP, fibrinogen, and tPA by treatment group

PlaceboMetforminLifestyle
Diabetes βDiabetes R2Diabetes βDiabetes R2Diabetes βDiabetes R2
Outcome: CRP
 Model A1: baseline CRP0.09 (−0.16, −0.02)0.28%0.10 (−0.19, −0.01)0.29%0.13 (−0.25, −0.01)0.27%
 Model A2: A1 + 0’ glucose−0.04 (−0.11, 0.04)0.04%−0.05 (−0.14, 0.04)0.07%−0.031 (−0.16, 0.09)0.01%
 Model A3: A1 + 0’ insulin0.09 (−0.17, −0.01)0.26%0.12 (−0.22, −0.02)0.34%0.13 (−0.26, −0.002)0.27%
 Model A4: A1 + weight−0.06 (−0.13, 0.01)0.13%−0.08 (−0.16, 0.01)0.18%−0.01 (−0.13, 0.10)0.00%
 Model A5: fully adjusted−0.04 (−0.13, 0.04)0.06%−0.07 (−0.16, 0.03)0.11%−0.02 (−0.16, 0.11)0.01%
Outcome: tPA
 Model B1: baseline tPA0.60 (−0.99, −0.21)0.50%0.68 (−1.1, −0.24)0.53%1.1 (−1.6, −0.56)0.98%
 Model B2: B1 + 0’ glucose−0.23 (−0.64, 0.18)0.07%−0.22 (−0.67, 0.23)0.05%−0.31 (−0.86, 0.24)0.07%
 Model B3: B1 + 0’ insulin0.48 (−0.88, −0.08)0.33%0.52 (−0.95, −0.08)0.32%0.80 (−1.3, −0.26)0.53%
 Model B4: B1 + weight0.44 (−0.82, −0.05)0.29%0.51 (−0.92, −0.09)0.34%0.52 (−1.0, −0.01)0.24%
 Model B5: B1 + fully adjusted−0.14 (−0.54, 0.27)0.03%−0.16 (−0.59, 0.27)0.03%−0.11 (−0.64, 0.42)0.01%
Outcome: Fibrinogen
 Model C1: baseline fibrinogen10 (−19, −2.1)0.35%−9.0 (−18, 0.05)0.24%−7.4 (−19, 4.3)0.10%
 Model C2: C1 + 0’ glucose8.8 (−17, −0.03)0.22%−5.4 (−15, 3.9)0.08%−4.7 (−17, 7.7)0.03%
 Model C3: C1 + 0’ insulin10 (−19, −1.9)0.35%−8.7 (−18, 0.49)0.22%−5.8 (−18, 6.1)0.06%
 Model C4: C1 + weight9.5 (−18, −1.1)0.29%−8.2 (−17, 0.88)0.20%−5.6 (−18, 6.5)0.05%
 Model C5: C1 + fully adjusted8.5 (−17, 0.41)0.21%−5.1 (−15, 4.3)0.07%−5.7 (−18, 6.9)0.05%
  • The adjusted effect of diabetes on CRP, fibrinogen, and tPA over time are assessed separately for each treatment group in a series of five mixed models that include demographics (age, sex, and race/ethnicity), year of assessment, and the baseline value of the outcome (series 1); baseline and change in fasting glucose (series 2); baseline and change in fasting insulin (series 3); baseline and change in weight (series 4); and baseline levels and changes in fasting glucose, fasting insulin, and weight (series 5). Estimates of the diabetes effect in bold indicate significant β for diabetes at α = 0.05.